Substance Use Disorder Epidemiology Summary
- The SUD burden is concentrated within overlapping polysubstance cohorts rather than distributed across discrete single-substance populations. Opioid, stimulant and hallucinogen use disorders frequently coexist with additional SUDs, resulting in considerable overlap between disorder-level prevalence estimates. Aggregating these estimates is therefore likely to overstate the number of distinct affected individuals.
- Age of substance-use initiation emerges as a key upstream correlate of polysubstance burden. Earlier initiation of alcohol, cannabis and nicotine is associated with a greater burden of co-occurring SUD in adulthood, indicating that adult polysubstance patterns are partly seeded during adolescence. Trends in youth initiation therefore warrant monitoring as a forward-looking epidemiological signal.
- Cannabis use disorder (CUD) prevalence is concentrated among younger adults and declines substantially with age in the US. According to Han et al. (2026), past-year CUD prevalence in 2024 was 17.1% among males and 11.5% among females aged 21–34 years, compared with 14.9% and 14.5% among those aged 18–20 years, 10.4% and 5.6% among those aged 35–49 years, and 3.8% and 1.9% among those aged =50 years, respectively.
- AUD prevalence shows a pronounced sex disparity in Japan. A 2025 nationwide survey estimated past-year suspected AUD in 5.4% of men versus 0.8% of women, corresponding to approximately 3 million people nationally, highlighting the substantially higher AUD burden among Japanese men.
- Diagnostic accuracy for opioid use disorder (OUD) is constrained in patients receiving opioids for pain. Tolerance and withdrawal, core diagnostic features, occur as expected physiological responses to prescribed opioids, and DSM-5 therefore excludes them from the criteria in medically supervised use. Behavioral indicators, such as craving or use beyond the intended amount, may also reflect therapeutic intent rather than disorder.
DelveInsight’s “Substance Use Disorder Epidemiology, Forecast – 2036” report delivers an in depth understanding of SUD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2025 |
|
Geographies Covered |
ü North America : The US ü Europe: Germany, France, Italy, Spain and the UK ü Asia-Pacific: Japan |
|
SUD Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
|
Analysis |
|
Substance Use Disorder Understanding
Substance Use Disorder Overview and Diagnosis
SUD is characterized by impaired control over psychoactive substance use, increasing priority given to substance use over other activities, and continued use despite harmful consequences. It may involve alcohol, opioids, cannabis, stimulants, sedatives, nicotine, or multiple substances, with clinical manifestations including craving, tolerance, withdrawal, and functional impairment varying by substance and severity.
Diagnosis is primarily clinical and assesses the pattern, consequences, and degree of control over substance use. The DSM-5-TR uses 11 criteria covering impaired control, social impairment, risky use, and pharmacological features, with SUD severity classified as mild, moderate, or severe based on the number of criteria met. Screening tools such as AUDIT for alcohol use and ASSIST for multiple substances can support identification of problematic substance use and inform further clinical assessment.
Further details related to country-based variations are provided in the report...
Substance Use Disorder Epidemiology
Key Findings from SUD Epidemiological Analysis and Forecast
- As per DelveInsight’s estimates, within EU4 and the UK, France recorded the highest diagnosed prevalent SUD population in 2025, with more than 15 million cases, while the UK had the lowest, at approximately 10 million cases.
- According to a 2020 US population-based study, approximately 27.5 million adults reported ever having a substance use problem, with prevalence highest among individuals aged 35–49 years (12.8%), followed by those aged 26–34 years (12.7%), and lowest among those aged 18–25 years (7.2%).
- According to the 2021 German Epidemiological Survey of Substance Abuse, problematic cannabis use affected approximately 1.3 million adults aged 18–64 years in Germany, with prevalence of 3.4% among men versus 1.6% among women, indicating a higher burden of problematic cannabis use among males.
- In 2025, the substance type-specific distribution of diagnosed prevalent SUD cases in Japan was highest for tobacco use disorder (~85%) and lowest for cannabis use disorder (<1%).
Industry Experts and Physician Views for Substance Use Disorder (SUD)
To keep up with SUD dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the SUD epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 20+ KOLs to gather insights at country level. Center such as Johns Hopkins University/Hospital, Yale School of Medicine, King’s College London, South London and Maudsley NHS Foundation Trust, Charité – Universitätsmedizin Berlin, National Center of Neurology and Psychiatry (NCNP), Kurihama Medical and Addiction Center, etc. were contacted.
Their opinion helps understand, validate, highlight and provide epidemiological context for SUD.
| Region | Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) |
|
United States |
“Polysubstance use should not be interpreted as a collection of independent substance-specific disorders. Overlapping patterns of use can materially alter both the clinical presentation and the way SUD burden is measured, making single-substance prevalence estimates an incomplete representation of the affected population. A more integrated characterization of polysubstance patterns could therefore improve epidemiological assessment and help identify distinct patient subgroups with different disease trajectories.” |
|
Germany |
“SUD remains substantially under recognized in routine clinical practice, meaning the diagnosed population may not fully capture the underlying epidemiological burden. Greater emphasis on systematic, standardized, and nonjudgmental screening could improve case identification and help narrow the gap between individuals experiencing problematic substance use and those formally recognized as having SUD.” |
Note: Detailed assessment of KOL Views will be provided in the full report on SUD...
Scope of the Substance Use Disorder Epidemiology Report
- The report covers a segment of key events, an executive summary, a descriptive overview of SUD, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Substance Use Disorder Epidemiology Report Insights
- SUD Patient Population Forecast
Substance Use Disorder Epidemiology Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
Explore the Substance Use Disorder Market Insight, Epidemiology, and Forecast to 2036 for emerging therapies, market trends, competitive insights, and growth opportunities.
FAQs
- What are the disease risks, burdens, and unmet needs of SUD?
- What will be the growth opportunities across the 7MM concerning the patient population with SUD?
- What is the SUD prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What is the historical and forecasted SUD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy Substance Use Disorder Epidemiology Report
- Insights on SUD burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- Clear methodology, validated assumptions, and data-driven rationale to assess the SUD epidemiology analysis and patient population trends.


-pipeline.png&w=256&q=75)
